- R&D
BioMed X Launches XBridge Program to Support U.S. Reacsearchers Amid NIH Funding Cuts
As research institutions throughout the United States grapple with increasing instability, many are being forced to respond to the growing consequences of widespread funding...Taiho spends $400 million with a Swiss partner to “turbocharge” three ADCs to the clinic
Taiho Pharmaceutical has paid Otsuka $400 million in upfront purchase of the Araris Biotech ADC linker platform in Switzerland. Araris collaborated with Taiho Pharmaceutical after...Élancé Therapeutics Joins the Race to Develop Next-Generation Obesity Therapies
China-based Harbour BioMed has recently announced the establishment of a new biotechnology company, Élancé Therapeutics. This initiative is focused on developing bispecific antibodies designed...Roche Comes Out With Novel ‘Sequencing-By-Expansion’ Approach
Roche has proposed a fresh kind of genetic analysis. This process, which the company refers to as sequencing-by-expansion, is a patented technique that involves...
- Clinical
VelaVigo Bio Strikes Second Major Licensing Agreement, Transfers Bispecific Rights to Ollin Biosciences
In a continued series of strategic moves, VelaVigo Bio, a biotechnology firm based in Shanghai, has finalized its second significant transaction within a six-month...Lilly’s Orforglipron Demonstrates Semaglutide-Like Efficacy in Phase 3 Type 2 Diabetes Trial
Eli Lilly’s oral GLP-1 receptor agonist orforglipron has met its primary efficacy endpoint in a Phase 3 trial, showing reductions in A1C and body...The late-stage research of Bristol Myers’ heart disease medication falls short of its primary objectives
Bristol Myers Squibb disclosed that its drug stavartanate did not successfully improve functional capacity or symptom intensities in heart disease patients, thus failing to...Pfizer Decides Against Pursuing Lead Obesity Asset Amid Liver Safety Concerns
Pfizer said that it had discovered a possible instance of medication-induced liver impairment and, as a result, would no longer be investing in the...
- Commercial
Biolinq Secures $100 Million to Advance Glucose Biosensor and Expand Commercialization Plans
Biolinq has announced the successful closure of a $100 million venture capital investment round aimed at finalizing the development of its wearable glucose biosensor....Sanofi Deepens Autoimmune Push with $1.8B AI Biotech Deal
Sanofi’s ambition to become a dominant force in immunology continues to take shape, as the French pharmaceutical giant signs a deal worth up to...Merck Signs $493M Agreement to Use Cyprumed’s Oral Peptide Platform
Merck & Co. is taking a significant step toward transforming its peptide therapies into convenient oral tablets through a licensing agreement worth up to...
- Technology
J&J MedTech presents the first Ottava surgical robot clinical cases
Johnson & Johnson MedTech successfully conducted the initial clinical use of Ottava surgical robot through a minimally invasive gastric bypass procedure in Texas. The system...Wisp Launches Weight Care Vertical for Women with Hormonal Imbalances
Common conditions in women such as PCOS, menopause, and endometriosis often lead to hormonal imbalances, resulting in irregular weight patterns. Wisp’s new weight care...PicnicHealth Launches New Service Bringing Observational Clinical Trials to the Virtual Realm
Health technology company PicnicHealth has launched a new product, Virtual Site, which allows researchers to carry out clinical trials remotely. This innovation is targeted...Elon Musk Announces Neuralink’s Second Brain-Computer Chip Implantation in a Patient
Neuralink, founded by Elon Musk, revealed that it has placed its device in the second human trial subject. The therapeutic application of the technology...
- Insights
The now-urgent automation agenda: out-of-control regulatory workloads necessitate AI adoption
A new independent survey of senior US pharma regulatory professionals suggests that commitment to AI investment is much higher than might be expected, although...Improving life science R&D outcomes with AI
Ben Sidders - 0Maximizing the potential AI/data-driven model of drug discovery requires the technology’s full integration into R&D. Biorelate’s Dr Ben Sidders explains. Pharma R&D latest disruption is...The medical device sector’s surging regulatory burden: how are suppliers coping?
Regulators around the world are increasing their scrutiny of medical devices as these become more critical to patient outcomes. Referencing new research, Peter Muller...The Future of Gene Therapies: Three Trends
“Maps don’t show you where you will go in life, they show you where you might go.”—John Green Over...
- Podcast
- Awards
- More
- R&D
BioMed X Launches XBridge Program to Support U.S. Reacsearchers Amid NIH Funding Cuts
As research institutions throughout the United States grapple with increasing instability, many are being forced to respond to the growing consequences of widespread funding...Taiho spends $400 million with a Swiss partner to “turbocharge” three ADCs to the clinic
Taiho Pharmaceutical has paid Otsuka $400 million in upfront purchase of the Araris Biotech ADC linker platform in Switzerland. Araris collaborated with Taiho Pharmaceutical after...Élancé Therapeutics Joins the Race to Develop Next-Generation Obesity Therapies
China-based Harbour BioMed has recently announced the establishment of a new biotechnology company, Élancé Therapeutics. This initiative is focused on developing bispecific antibodies designed...Roche Comes Out With Novel ‘Sequencing-By-Expansion’ Approach
Roche has proposed a fresh kind of genetic analysis. This process, which the company refers to as sequencing-by-expansion, is a patented technique that involves...
- Clinical
VelaVigo Bio Strikes Second Major Licensing Agreement, Transfers Bispecific Rights to Ollin Biosciences
In a continued series of strategic moves, VelaVigo Bio, a biotechnology firm based in Shanghai, has finalized its second significant transaction within a six-month...Lilly’s Orforglipron Demonstrates Semaglutide-Like Efficacy in Phase 3 Type 2 Diabetes Trial
Eli Lilly’s oral GLP-1 receptor agonist orforglipron has met its primary efficacy endpoint in a Phase 3 trial, showing reductions in A1C and body...The late-stage research of Bristol Myers’ heart disease medication falls short of its primary objectives
Bristol Myers Squibb disclosed that its drug stavartanate did not successfully improve functional capacity or symptom intensities in heart disease patients, thus failing to...Pfizer Decides Against Pursuing Lead Obesity Asset Amid Liver Safety Concerns
Pfizer said that it had discovered a possible instance of medication-induced liver impairment and, as a result, would no longer be investing in the...
- Commercial
Biolinq Secures $100 Million to Advance Glucose Biosensor and Expand Commercialization Plans
Biolinq has announced the successful closure of a $100 million venture capital investment round aimed at finalizing the development of its wearable glucose biosensor....Sanofi Deepens Autoimmune Push with $1.8B AI Biotech Deal
Sanofi’s ambition to become a dominant force in immunology continues to take shape, as the French pharmaceutical giant signs a deal worth up to...Merck Signs $493M Agreement to Use Cyprumed’s Oral Peptide Platform
Merck & Co. is taking a significant step toward transforming its peptide therapies into convenient oral tablets through a licensing agreement worth up to...
- Technology
J&J MedTech presents the first Ottava surgical robot clinical cases
Johnson & Johnson MedTech successfully conducted the initial clinical use of Ottava surgical robot through a minimally invasive gastric bypass procedure in Texas. The system...Wisp Launches Weight Care Vertical for Women with Hormonal Imbalances
Common conditions in women such as PCOS, menopause, and endometriosis often lead to hormonal imbalances, resulting in irregular weight patterns. Wisp’s new weight care...PicnicHealth Launches New Service Bringing Observational Clinical Trials to the Virtual Realm
Health technology company PicnicHealth has launched a new product, Virtual Site, which allows researchers to carry out clinical trials remotely. This innovation is targeted...Elon Musk Announces Neuralink’s Second Brain-Computer Chip Implantation in a Patient
Neuralink, founded by Elon Musk, revealed that it has placed its device in the second human trial subject. The therapeutic application of the technology...
- Insights
The now-urgent automation agenda: out-of-control regulatory workloads necessitate AI adoption
A new independent survey of senior US pharma regulatory professionals suggests that commitment to AI investment is much higher than might be expected, although...Improving life science R&D outcomes with AI
Ben Sidders - 0Maximizing the potential AI/data-driven model of drug discovery requires the technology’s full integration into R&D. Biorelate’s Dr Ben Sidders explains. Pharma R&D latest disruption is...The medical device sector’s surging regulatory burden: how are suppliers coping?
Regulators around the world are increasing their scrutiny of medical devices as these become more critical to patient outcomes. Referencing new research, Peter Muller...The Future of Gene Therapies: Three Trends
“Maps don’t show you where you will go in life, they show you where you might go.”—John Green Over...
- Podcast
- Awards
- More
Editor Picks
Eisai and Biogen’s injectable Alzehimer drug faces setback from the FDA
First, due to the burden on its patients and healthcare infrastructure, and now with...
J&J Strikes a $245 CAR-T Deal With Cellular Biomedicine
Johnson & Johnson's Janssen Biotech subsidiary has just paid $245 million upfront...
Deal on Cancer ADC Gets Canceled by Eisai and Bristol Myers
Eisai will terminate a partnership on a dual-action lung and ovarian cancer medication with...
Must Read
Roche offers $50 billion to US pharma production in response to the tariff threat
Roche, the drugmaker giant, announced its interest in investing $50 billion over five years...
Biolinq Secures $100 Million to Advance Glucose Biosensor and Expand Commercialization Plans
Biolinq has announced the successful closure of a $100 million venture capital investment round...
VelaVigo Bio Strikes Second Major Licensing Agreement, Transfers Bispecific Rights to Ollin Biosciences
In a continued series of strategic moves, VelaVigo Bio, a biotechnology firm based in...
About Us
Life Sciences Voice is the leading resource for life sciences executives to get crucial insights, explore the latest innovations, and learn about industry trends. Life Sciences Voice provides the community with thought-provoking commentary in multiple formats covering a range of issues from drug discovery to commercial success.
Contact us: reachout(at)lifescivoice.com